Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fever of unknown origin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Fever of unknown origin. Displaying page 1 of 1.
    EudraCT Number: 2007-005823-14 Sponsor Protocol Number: I07005 Start Date*: 2008-04-03
    Sponsor Name:CHU de LIMOGES
    Full Title: Impact de la TEP dans la stratégie diagnostique des fièvres d'origine indéterminée ou des syndromes inflammatoires nus chez l'adulte immunocompétent.
    Medical condition: Les fièvres d'origine indéterminée ou les syndromes inflammatoires nus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016563 Fever of unknown origin LLT
    9.1 10061218 Inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-003745-40 Sponsor Protocol Number: GS-IT-131-0151 Start Date*: 2005-02-07
    Sponsor Name:GILEAD SCIENCES S.R.L.
    Full Title: Phase II pilot study on safety of administration of 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment ( day 50-8t...
    Medical condition: Fungal Infection High risk patients undergoing allogeneic stem-cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000103-16 Sponsor Protocol Number: RC13_0008 Start Date*: 2013-06-21
    Sponsor Name:CHU de Nantes
    Full Title: Antifungal prophylaxis with Micafungin after cord blood allogeneic stem cell transplantation.
    Medical condition: Adult patients receiving allo-Stem Cell Transplantation using Cord Blood as source of stem cells
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10010980 Cord blood transplant therapy PT
    18.0 10042613 - Surgical and medical procedures 10049085 Antifungal prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001546-25 Sponsor Protocol Number: NL48960.029.14 Start Date*: 2015-01-06
    Sponsor Name:VU University Medical Center
    Full Title: Short versus extended antibiotic treatment with a carbapenem for high-risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open-label non-inferiori...
    Medical condition: Febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    19.1 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    19.1 10021881 - Infections and infestations 10003999 Bacteremia LLT
    19.1 10021881 - Infections and infestations 10007810 Catheter related infection LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028566 Myeloma LLT
    19.1 10021881 - Infections and infestations 10062957 Catheter bacteraemia LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    19.1 10021881 - Infections and infestations 10056520 Catheter site infection PT
    19.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001506-16 Sponsor Protocol Number: IB 2005-33 Start Date*: 2008-07-07
    Sponsor Name:Institut Bergonié
    Full Title: Diffuse large B cell non-hodgkin's lymphoma in the vulnerable/frail elderly. A multicentrix randomized phase II trial with emphasis on geritaric assesment and quality of life.
    Medical condition: Vulnerable/Frail elderly patients older than 70 with diffuse large B-cell lymphoma stage II, III, or IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001758-14 Sponsor Protocol Number: 201677 Start Date*: 2015-12-18
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis (GCA)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10047065 - Vascular disorders 10047116 Vascular inflammations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003774-16 Sponsor Protocol Number: EIFFEL Start Date*: 2016-06-07
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases
    Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 24 20:01:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA